Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Celgene Cp Cvr (CELGZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]


See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
0.76 +68.12%
on 02/20/19
1.65 -22.56%
on 03/12/19
+0.37 (+40.41%)
since 02/15/19
0.35 +265.06%
on 12/28/18
1.65 -22.56%
on 03/12/19
+0.48 (+59.71%)
since 12/14/18
0.11 +1,061.55%
on 03/20/18
2.65 -51.78%
on 08/10/18
+0.92 (+254.92%)
since 03/15/18

Most Recent Stories

More News
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights

OncoMed Pharmaceuticals, Inc. ("OncoMed") (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board...

OMED : 0.96 (-3.13%)
CELGZ : 1.28 (-2.47%)
Advancing Clinical Trials for Leukemia Patients is Helping Improve Survival Rate

According to the Leukemia & Lymphoma Society, the world's largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are...

AKTX : 4.59 (+12.50%)
CELG : 88.34 (-0.14%)
LLY : 124.27 (+0.27%)
GERN : 1.62 (-2.99%)
CELGZ : 1.28 (-2.47%)
MBRX : 1.34 (+5.51%)
Celgene Provides Update on ABRAXANE(R) Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

--Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination with gemcitabine vs. gemcitabine alone for patients with surgically resected pancreatic...

CELG : 88.34 (-0.14%)
CELGZ : 1.28 (-2.47%)
Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment...

CELG : 88.34 (-0.14%)
CELGZ : 1.28 (-2.47%)
Starboard Mails Letter with Important Message to All Bristol-Myers Squibb Stockholders

Starboard Value LP (together with its affiliates, "Starboard"), a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(NYSE:BMY), today announced that it has mailed a letter to...

CELGZ : 1.28 (-2.47%)
BMY : 49.84 (-0.24%)
Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene

--Bristol-Myers Squibb Has a Strong Track Record of Financial and Operational Outperformance

CELG : 88.34 (-0.14%)
CELGZ : 1.28 (-2.47%)
BMY : 49.84 (-0.24%)
U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for fedratinib and granted a Priority Review....

CELG : 88.34 (-0.14%)
CELGZ : 1.28 (-2.47%)
Gainey McKenna & Egleston Announces that It Filed a Class Action Lawsuit Against SI Financial Group, Inc. (SIFI) And Its Directors

Gainey McKenna & Egleston announces that it filed a class action lawsuit against SI Financial Group, Inc. ("SIFI" or the "Company") (Nasdaq: SIFI) and its board of directors (the "Board"), on behalf of...

CELGZ : 1.28 (-2.47%)
SIFI : 14.53 (+0.35%)
Starboard Delivers Open Letter to Bristol-Myers Squibb Stockholders

Starboard Value LP (together with its affiliates, "Starboard"), a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(NYSE:BMY), today announced that it has delivered an open...

CELGZ : 1.28 (-2.47%)
BMY : 49.84 (-0.24%)
Wellington Management Does Not Support Bristol-Myers Squibb's Acquisition of Celgene Corporation

Wellington Management Company LLP ("Wellington"), one of the world's largest independent investment management firms, managing approximately $1 trillion in assets on behalf of its clients...

CELG : 88.34 (-0.14%)
CELGZ : 1.28 (-2.47%)
BMY : 49.84 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar